What is the recommended dose of sunitinib in mg?

Sunitinib is a targeted drug widely used in the treatment of a variety of malignant tumors, especially in the treatment of renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST). The drug inhibits the formation of tumor blood vessels by blocking some key receptors, such as vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), etc., thereby effectively inhibiting tumor growth and metastasis. The recommended dosage regimen can be adjusted based on the patient's specific condition and tolerance.

Generally, the recommended standard dose of sunitinib is 50 mg orally once daily. This program usually uses a "4/2" treatment cycle, that is, the patient takes the drug for 4 weeks, followed by a 2-week break. This treatment cycle aims to maximize the inhibition of tumor growth through four consecutive weeks of drug action, while giving the patient a two-week rest period to allow the body to recover to a certain extent and alleviate the possible side effects of the drug. The advantage of this program is that through periodic medication, it can effectively control tumors while reducing the accumulation of long-term side effects.

For some patients, especially those who may have tolerance issues with standard doses, doctors may be able to adjust the dose. At this time, a dose of 37.5 mg orally once daily may be used, and no withdrawal period is required. This continuous regimen is suitable for patients who require long-term treatment and can tolerate the drugs well. It is common in some cases with more stubborn diseases.

In actual treatment, patients should take sunitinib in strict accordance with the dosage according to the doctor's instructions, and undergo regular medical examinations to monitor the impact of the drug on the body. Through personalized dose adjustment, the therapeutic effect of sunitinib can be maximized while minimizing side effects.

Reference materials:https://www.sutent.com/